Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-002369-14 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
A substantial proportion of patients with alcohol use disorder does not respond to available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study aims to determine the feasibility and preliminary clinical efficacy of psilocybin-assisted therapy as a complementary intervention during inpatient rehabilitation for severe alcohol use disorder, and to characterize associated changes in the two key neurocognitive systems identified by dual-process models of addiction.
In this double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial, 62 participants aged 21-64 years will be enrolled to undergo psilocybin-assisted therapy within the context of a 4-week inpatient rehabilitation for severe alcohol use disorder. The experimental group will receive a high dose of psilocybin (30 mg), whereas the control group will receive an active placebo dose of psilocybin, both within the context of a brief standardized psychotherapeutic intervention. The primary clinical outcome is the between-group difference in terms of the change in percentage of heavy drinking days from baseline to four weeks post-hospital discharge, whilst safety and feasibility metrics will also be reported as primary outcomes. Key secondary assessments include between-group differences in terms of changes in 1) drinking behavior parameters up to six months post-hospital discharge, 2) phosphatidyl-ethanol blood concentration, an objective biomarker of alcohol consumption, 3) symptoms of depression, anxiety, trauma, and global functioning, 4) neuroplasticity and key neurocognitive mechanisms associated with addiction, 5) psychological processes and alcohol-related parameters.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| high dose psilocybin | Experimental | 31 participants will receive a single administration of 30mg psilocybin provided within the context of a brief standardized psychotherapeutic intervention. |
|
| low dose psilocybin (active placebo) | Placebo Comparator | 31 participants will receive a single administration of a very low dose of psilocybin (active placebo) provided within the context of a brief standardized psychotherapeutic intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Psilocybin (high dose) | Drug | Psilocybin-assisted therapy |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Primary clinical outcome: change in percentage of heavy drinking days | The primary clinical outcome is the difference between the two treatment arms in terms of change from baseline (going back 8 weeks pre-enrolment) to 4 weeks post-hospital discharge (week 1 to 4 post-discharge) in the percentage of heavy drinking days. A heavy drinking day is defined as a day with ≥ 5 standard drinks/60g of alcohol for males, and ≥ 4 standard drinks/48g of alcohol for females. Alcohol consumption will be measured using the Timeline Follow-Back method (Sobell & Sobell, 1992), a semi-structured interview that provides estimates of the daily quantity, frequency, and pattern of alcohol (and other drugs) use during a set time period. The method has demonstrated adequate to excellent reliability and validity over a wide range of studies and clinical contexts (Carey, 1997; Sobell et al., 1996). | Baseline (going back to 8 weeks pre-enrolment) to 4 weeks post-hospital discharge |
| Feasibility: recruitment and retention rate | Recruitment and retention rate will be recorded and reported. A consort diagram displaying participant retention at each phase of the recruitment, screening and data collection process will be presented. We will report the numbers of individuals provided with participant information sheets who subsequently decided not to participate in the trial, number that underwent screening and number of drop-outs. For full transparency on inclusivity, information on the demographics and reason for exclusion will be reported from the screening dataset. | Recruitment rate: at screening and enrolment. Retention rate: at each study visit |
| Safety: adverse events | Adverse events will be systematically assessed at each study visit and follow-ups. Adverse events summary tables will display the total number of participants reporting an adverse event and the percentage of participants (%) with an adverse event. | At each study visit |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Heavy Drinking Days | Alcohol consumption as measured with the Timeline Follow Back Method | from pre-hospitalisation (up to 8 weeks pre-hospitalization) to 6 months post-hospital discharge (week 5 to 26 weeks) |
| Drinks per Day |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Laetitia Vanderijst, M.Sc. | Contact | 02 477 22 33 | laetitia.vanderijst@ulb.be |
| Name | Affiliation | Role |
|---|---|---|
| Charles Kornreich, M.D. Ph.D. | Brugmann University Hospital, Free University of Brussels | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brugmann University Hospital | Recruiting | Brussels | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36001306 | Background | Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Oct 1;79(10):953-962. doi: 10.1001/jamapsychiatry.2022.2096. | |
| 38279085 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D011562 | Psilocybin |
| ID | Term |
|---|---|
| D026121 | Indole Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
Not provided
Not provided
Monocentric, randomized, double-blind, placebo-controlled, 1:1 parallel-group 7-month clinical trial comparing the effects of a high dose of psilocybin to those of a low dose of psilocybin (active placebo) provided within the context of a brief standardized psychotherapeutic intervention in 62 participants with severe alcohol use disorder.
Not provided
Not provided
Not provided
| Active placebo (low dose of psilocybin) |
| Drug |
Placebo-assisted therapy |
|
Alcohol consumption as measured with the Timeline Follow Back Method
| from pre-hospitalisation (up to 8 weeks pre-hospitalization) to 4 weeks and 6 months post-hospital discharge |
| Percent Days Abstinent | Alcohol consumption as measured with the Timeline Follow Back Method | from pre-hospitalisation (up to 8 weeks pre-hospitalization) to 4 weeks and 6 months post-hospital discharge |
| EEG-derived auditory long-term potentiation | Index of cortical neuroplasticity | Neuroplasticity EEG data will be collected pre-dosing and twice post-dosing (+1 day, +7 days) |
| EEG-derived alcohol cue reactivity | EEG data will be collected pre-dosing and twice post-dosing (+1 day, +7 days) |
| EEG-derived inhibitory control | EEG data will be collected pre-dosing and twice post-dosing (+1 day, +7 days) |
| Psychological flexibility | The Acceptance and Action Questionnaire II (AAQII; Bond et al., 2011) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Connectedness | The Watts Connectedness Scale (WCS; Watts et al., 2022) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Interoception | The Multidimensional Assessment of Interoceptive Awareness (MAIA; Mehling et al., 2012) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Depressive symptoms | Beck Depression Inventory (BDI; Beck et al., 1961) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Anxiety symptoms | StateTrait Anxiety Inventory - trait subscale (STAI; Spielberger et al., 1983) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Trauma symptoms | International Trauma Questionnaire (ITQ; Cloitre et al., 2018) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Substance use recovery (patient reported outcome measure - PROM) | Substance Use Recovery Evaluator (SURE; Neale et al., 2016) | Baseline as well as four weeks, three and six months post-hospital discharge. |
| Alcohol craving | Penn Alcohol Craving Scale (PACS; Flannery et al., 1999) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Abstinence self-efficacy | Alcohol Abstinence Self-Efficacy Scale (AASE; DiClemente et al., 1994) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Readiness to change | Likert-scale ratings of the participant's perception of 1) the importance of change in drinking; 2) confidence of ability to change; 3) readiness for change; 4) Commitment to the goal of abstinence (Bogenschutz et al., 2022) | Baseline, one day prior to psilocybin administration, one week post-psilocybin administration, as well as four weeks, three and six months post-hospital discharge. |
| Derived |
| Vanderijst L, Hever F, Buot A, Daure C, Benoit J, Hanak C, Veeser J, Morgieve M, Campanella S, Kornreich C, Mallet L, Leys C, Noel X. Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. BMC Psychiatry. 2024 Jan 26;24(1):77. doi: 10.1186/s12888-024-05502-y. |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D014363 | Tryptamines |
| D054836 | Indolizidines |
| D007212 | Indolizines |